Stocktoria
BIODESIX INC BDSX
Nasdaq · XNAS · stock · Services-Medical Laboratories · website · IPO 2020-10-28
BIODESIX INC statistics & valuation
Market cap$241.7M
P / S2.7×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -31.5% | -48.4% | -84.2% | -132.4% | -75.1% |
| Net margin | -39.8% | -60.2% | -106.2% | -171.3% | -79.2% |
| FCF margin | -26.6% | -72.7% | -93.3% | -126.3% | -55.9% |
| Return on assets | -40.3% | -44.1% | -52.6% | -70.4% | -56.7% |
| Return on equity | 1430.6% | -205.6% | -1138.6% | -317.6% | -218.8% |
| Debt / equity | -20.29× | 1.92× | 8.75× | 1.46× | 0.51× |
| Current ratio | 1.86 | 2.76 | 1.19 | 2.34 | 1.51 |
| Revenue growth | 24.1% | 45.3% | 28.5% | -29.9% | 19.6% |
Source: SEC EDGAR filings · CIK 0001439725 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.